| Patient | Charlotte Brontë |
|---|---|
| Date of birth | 1987-04-21 |
| Identifiers | MRN HR-NI025-SYN; SSN (made up) 000-25-3804 |
| Document date | 2026-01-29 |
| Author | Eleanor Thwaite, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Vomiting everything for a day and a half, dizzy when she stands, and passing little urine. [S]
Ms. Brontë is a 38-year-old woman in her first pregnancy, at 9 weeks 3 days by a 7-week dating scan, with moderate nausea and vomiting of pregnancy treated for two weeks with doxylamine-pyridoxine, raised nine days ago to four tablets a day, and metoclopramide 10 mg three times a day added at the same visit. She was a little better for two days and then worse. For the last 36 hours she has kept down neither fluids nor tablets and has vomited eight to ten times a day, including bile. She feels faint when she stands, her mouth is dry, and she has passed a small amount of dark urine twice today. She has had no abdominal pain, fever, diarrhea, headache, visual change, confusion, unsteadiness, palpitations, or tremor, and no vaginal bleeding. Metoclopramide has caused no restlessness or abnormal movements. She weighs 42.6 kg, 7.4 percent below her pre-pregnancy weight of 46.0 kg. Her PUQE-24 score today is 14 (severe). A family member drove her in. [S]
| Element | Detail |
|---|---|
| Onset | Nausea and vomiting from about 6 weeks; unable to keep fluids down for 36 hours |
| Severity | PUQE-24 score 14 (severe); vomiting eight to ten times a day |
| Associated signs and symptoms | Faint on standing, dry mouth, little dark urine |
| Pertinent negatives | No pain, fever, diarrhea, bleeding, headache, confusion, unsteadiness, or visual change |
| Treatment so far | Doxylamine-pyridoxine four tablets a day and metoclopramide 10 mg three times a day; tablets now vomited |
| Weight | 42.6 kg, 7.4 percent below her pre-pregnancy weight |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Weak and lightheaded on standing; no fever |
| Gastrointestinal | Positive | Vomiting eight to ten times a day; no abdominal pain, diarrhea, or blood in the vomit |
| Genitourinary | Positive | Small amounts of dark urine; no burning or frequency; no vaginal bleeding |
| Neurological | Negative | No headache, confusion, double vision, or unsteadiness |
| Endocrine | Negative | No palpitations, tremor, or heat intolerance |
| Psychiatric | Positive | Low and frightened by how ill she feels; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe) | One tablet by mouth daily | Oral route | 2026-01-13 | active | S |
| Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, two tablets by mouth at bedtime | Two tablets by mouth at bedtime | Oral route | 2026-01-13 to 2026-01-20 | completed | S |
| Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day) | One tablet in the morning, one mid-afternoon, and two at bedtime | Oral route | 2026-01-20 | active | S |
| Metoclopramide 10 mg oral tablet, one tablet by mouth three times a day before meals | One tablet by mouth three times a day, 30 minutes before meals | Oral route | 2026-01-20 to 2026-01-29 | completed | S |
| Sodium chloride 0.9% with potassium chloride 20 mmol per liter, 1000 mL intravenously over 8 hours | 1000 mL over 8 hours, guided by daily electrolytes | Intravenous route | 2026-01-29 to 2026-02-01 | completed | S |
| Thiamine 100 mg intravenously daily, the first dose before any dextrose | 100 mg intravenously once daily; first dose before any dextrose-containing fluid | Intravenous route | 2026-01-29 to 2026-02-01 | completed | S |
| Ondansetron 4 mg intravenously every 8 hours | 4 mg by slow intravenous injection every 8 hours | Intravenous route | 2026-01-29 to 2026-02-01 | completed | S |
| Enoxaparin 20 mg subcutaneously once daily during the admission (weight under 50 kg) | 20 mg (0.2 mL) subcutaneously once daily while in hospital | Subcutaneous route | 2026-01-29 to 2026-02-01 | completed | S |
| Magnesium sulfate 2 g in 50 mL intravenously over 1 hour, once | 2 g intravenously over 1 hour, one dose | Intravenous route | 2026-01-29 to 2026-01-29 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-29 | Body height | 152 | cm | S |
| 2026-01-29 | Body weight | 42.6 | kg | S |
| 2026-01-29 | Body mass index (BMI) [Ratio] | 18.4 | kg/m2 | S |
| 2026-01-29 | Systolic blood pressure | 96 | mm[Hg] | S |
| 2026-01-29 | Diastolic blood pressure | 60 | mm[Hg] | S |
| 2026-01-29 | Heart rate | 108 | /min | S |
| 2026-01-29 | Respiratory rate | 16 | /min | S |
| 2026-01-29 | Body temperature | 36.9 | Cel | S |
| 2026-01-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-29 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 11-15.5 g/dL | Normal | S |
| 2026-01-29 | Sodium [Moles/volume] in Serum or Plasma | 133 | mmol/L | 135-145 mmol/L | Low | S |
| 2026-01-29 | Potassium [Moles/volume] in Serum or Plasma | 3.1 | mmol/L | 3.5-5.1 mmol/L | Low | S |
| 2026-01-29 | Chloride [Moles/volume] in Serum or Plasma | 94 | mmol/L | 98-107 mmol/L | Low | S |
| 2026-01-29 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 31 | mmol/L | 22-29 mmol/L | High | S |
| 2026-01-29 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 | mg/dL | 6-20 mg/dL | High | S |
| 2026-01-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.71 | mg/dL | 0.4-0.9 mg/dL | Normal | S |
| 2026-01-29 | Glucose [Mass/volume] in Serum or Plasma | 68 | mg/dL | 70-99 mg/dL | Low | S |
| 2026-01-29 | Magnesium [Mass/volume] in Serum or Plasma | 1.6 | mg/dL | 1.7-2.2 mg/dL | Low | S |
| 2026-01-29 | Phosphate [Mass/volume] in Serum or Plasma | 2.6 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-01-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 66 | U/L | 7-35 U/L | High | S |
| 2026-01-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 49 | U/L | 10-35 U/L | High | S |
| 2026-01-29 | Thyrotropin [Units/volume] in Serum or Plasma | 0.03 | m[IU]/L | 0.1-2.5 mIU/L | Low | S |
| 2026-01-29 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 2.1 | ng/dL | 0.8-1.8 ng/dL | High | S |
| 2026-01-29 | Ketones [Mass/volume] in Urine by Test strip | 80 | mg/dL | <=0 mg/dL | High | S |
Vital signs recorded on 2026-01-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Slight, pale, and tired; retching into a bowl; alert |
| Hydration | Dry mucous membranes; capillary refill 3 seconds; blood pressure 96/60 mmHg and pulse 108 seated, 88/56 mmHg and 124 standing |
| Neck | Thyroid not enlarged; no bruit |
| Eyes | No proptosis or lid lag; no nystagmus |
| Cardiovascular | Sinus tachycardia; no murmur |
| Abdomen | Soft and non-tender; no guarding; uterus not yet palpable |
| Neurological | Oriented; normal eye movements; no ataxia; no tremor |
| Fetal | Bedside ultrasound: fetal cardiac activity present |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First pregnancy at 38 (elderly primigravida), single live intrauterine pregnancy dated by ultrasound at 7 weeks 1 day | active | confirmed | O09.519 | S — Synthetic modern prenatal care anchored to the documented report that she was pregnant when she died; the pregnancy itself is questioned in one source (CLM-0019). |
| Nausea and vomiting of pregnancy, moderate (PUQE-24 score 10), with early weight loss, under evaluation for hyperemesis gravidarum | resolved | confirmed | O21.9 | S — Synthetic presenting concern at the index visit, superseded by the hyperemesis gravidarum diagnosis at the sick visit; her documented "perpetual nausea" is D and the hyperemesis reading of it is R. |
| Hyperemesis gravidarum with metabolic disturbance: unable to keep fluids down, 7.4 percent weight loss, dehydration, hypokalemia, hyponatremia, hypochloremic alkalosis, low magnesium, and raised transaminases; PUQE-24 score 14 | active | confirmed | O21.1 | S — Synthetic modern diagnosis linked to her documented final illness and the retrospective hyperemesis interpretation; it is not asserted as her historical diagnosis. |
| Gestational transient thyrotoxicosis: suppressed TSH and mildly raised free T4 with hyperemesis, no goiter, eye signs, or tremor; no treatment needed | active | confirmed | O99.281 | S — Synthetic finding that teaches the thyroid tests in hyperemesis; it echoes no documented illness. |
Guideline basis: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024); Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium (Green-top Guideline No. 37a) (2015); 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum (2017)
Follow-up: Prenatal review about ten days after admission, with electrolytes repeated within a week of discharge. Return the same day if vomiting returns and she cannot keep fluids down for 24 hours, if she feels faint, or if confusion, unsteadiness, or double vision develop. Next scheduled visit 2026-02-10: prenatal visit at 11 weeks: nausea and vomiting review and cell-free DNA screening. [S]